调研速递|诺思格接受中金医药等50余家机构调研 透露业务发展精彩要点

Group 1 - The company, Norsg (Beijing) Pharmaceutical Technology Co., Ltd., has attracted significant attention in the industry, as evidenced by recent investor relations activities [1] - The investor relations activity was a targeted research event held from August 28 to September 11, 2025, with participation from over 50 securities, fund, and asset management institutions [2] - Key personnel from the company included Chairman and General Manager Wu Jie, Board Secretary and Vice General Manager Li Shuq, and Chief Financial Officer Zhao Qian [2] Group 2 - Order situation in August 2025 remained stable compared to the previous year and has begun to recover, correlating with the rebound in the Hong Kong biopharmaceutical sector [3] - The company's SMO business covers major cities in China with a workforce of approximately 1,500, focusing on long-term foreign enterprise clients while ensuring profit margins [3] - Gross margin is recovering due to controlled price decline in the industry and improved personnel efficiency, with potential for further increase if prices rise [3] - The first half of 2025 saw strong momentum in innovative drugs, driven by the recovery of the Hong Kong stock market and a prosperous overseas market [3] - New order volume in the first half of 2025 was comparable to the previous year, with slight increases in contract amounts and service fees [3] - The pricing for overseas statistical orders remains stable, while domestic statistical business prices are expected to stabilize and potentially recover [3] - The clinical trial hotspots include ADC, CAR-T, PD-1, and cell therapy products, with GLP-1 being a popular area [3] - The industry is witnessing increased investment in high-quality products and projects, with the company potentially benefiting from the recognition of Chinese data by multinational corporations [3]